RxDoctor Payments Data

Kenneth Judson, DO

Clinical Cardiac Electrophysiology · Morgantown, WVNPI 1770525891

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Boston Scientific at 54.0% of the total. Reporting peaked in 2023 at $1,327 and has fallen 54.7% since, to $600 in 2025.

$7,277in general payments, 2019–2025

Across 249 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$922
  • Abbott$359
  • Philips North America LLC$341
  • E.r. Squibb & Sons, L.L.C.$259
  • AstraZeneca$180
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$7,17799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$194,118
Medicare patients
1,317
Services billed
3,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$186,455
XareltoRivaroxaban23$33,300
EntrestoSacubitril/Valsartan17$18,176
Metoprolol Succinate107$1,845
Flecainide Acetate42$1,762
Amiodarone Hcl73$1,342
Metoprolol Tartrate24$197
Warfarin Sodium16$180
SotalolSotalol Hcl17$157
Verapamil ErVerapamil Hcl11$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$186,455154 claims
Johnson & JohnsonXarelto$49$33,30023 claims
NovartisEntresto$62$18,17617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →